Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study (Q45246341)

11 December 2017

title

Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study (English)

1 reference

11 December 2017

1 reference

1 reference

Runmei Li

1

1 reference

11 December 2017

Changli Wang

2

1 reference

11 December 2017

Liang Liu

3

1 reference

11 December 2017

Chunjuan Du

4

1 reference

11 December 2017

Shui Cao

5

1 reference

11 December 2017

Jinpu Yu

6

1 reference

11 December 2017

Shizhen Emily Wang

7

1 reference

11 December 2017

Xishan Hao

8

1 reference

11 December 2017

Xiubao Ren

9

1 reference

11 December 2017

Hui Li

10

1 reference

11 December 2017

publication date

13 May 2012

1 reference

Cancer Immunology, Immunotherapy

11 December 2017

published in

1 reference

11 December 2017

volume

61

1 reference

11 December 2017

issue

11

1 reference

11 December 2017

page(s)

2125-2133

1 reference

11 December 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Current treatments for advanced stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Developments in clinical cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Immune therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Synergistic antitumor effects of immune cell-viral biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1260-2

10.1007/S00262-012-1260-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1047019787

0 references

1 reference